These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
481 related articles for article (PubMed ID: 23055153)
1. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells. Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153 [TBL] [Abstract][Full Text] [Related]
2. CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells. Nishioka C; Ikezoe T; Yang J; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A Int J Cancer; 2014 Jan; 134(1):55-64. PubMed ID: 23797738 [TBL] [Abstract][Full Text] [Related]
3. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells. Nishioka C; Ikezoe T; Yang J; Yokoyama A PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299 [TBL] [Abstract][Full Text] [Related]
4. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo. Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444 [TBL] [Abstract][Full Text] [Related]
5. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A. Yang J; Ikezoe T; Nishioka C; Nobumoto A; Udaka K; Yokoyama A Int J Cancer; 2013 Dec; 133(11):2706-19. PubMed ID: 23686525 [TBL] [Abstract][Full Text] [Related]
6. Senescence effects of Angelica sinensis polysaccharides on human acute myelogenous leukemia stem and progenitor cells. Liu J; Xu CY; Cai SZ; Zhou Y; Li J; Jiang R; Wang YP Asian Pac J Cancer Prev; 2014 Jan; 14(11):6549-56. PubMed ID: 24377566 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1. Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889 [TBL] [Abstract][Full Text] [Related]
8. Live kinase B1 maintains CD34 Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012 [TBL] [Abstract][Full Text] [Related]
9. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells. Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991 [TBL] [Abstract][Full Text] [Related]
10. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410 [TBL] [Abstract][Full Text] [Related]
11. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML. Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758 [TBL] [Abstract][Full Text] [Related]
12. Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38- Leukemia Stem Cells Derived from KG1α Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway. Tang YL; Zhang CG; Liu H; Zhou Y; Wang YP; Li Y; Han YJ; Wang CL Med Sci Monit; 2020 Feb; 26():e918207. PubMed ID: 32037392 [TBL] [Abstract][Full Text] [Related]
13. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance. Zhi L; Wang M; Rao Q; Yu F; Mi Y; Wang J Cancer Lett; 2010 Oct; 296(1):65-73. PubMed ID: 20444543 [TBL] [Abstract][Full Text] [Related]
14. STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells. Takeuchi A; Nishioka C; Ikezoe T; Yang J; Yokoyama A Leuk Res; 2015 Aug; 39(8):897-905. PubMed ID: 26059451 [TBL] [Abstract][Full Text] [Related]
16. Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia. Sun Q; So CC; Yip SF; Wan TS; Ma SK; Chan LC Leuk Res; 2008 Sep; 32(9):1374-81. PubMed ID: 18372040 [TBL] [Abstract][Full Text] [Related]
17. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470 [TBL] [Abstract][Full Text] [Related]
18. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725 [TBL] [Abstract][Full Text] [Related]